

Parabolic Drugs Limited

Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh
Corporate Office: 9 AB, Taimoor Nagar, New Friends Colony, New Delhi
Audited Financial Results for the Year Ended 31st March, 2011

(Rs. Crores)

Particulars	Year ended 31/03/2011	Corresponding Previous Year Ended 31/03/2010
	Audited	Audited
a) Gross Sales	675.30	559.01
Less : Excise Duty	(59.28)	(45.12)
Net Sales/Income from Operations	616.02	513.89
(b) Other Operating Income	19.16	4.87
1. Total Income	635.18	518.76
2. Expenditure		
a) (Increase)/Decrease in stock in trade and work in progress	(89.78)	(52.06)
b) Consumption of Raw Materials	541.09	419.92
c) Employees Cost	16.93	13.90
d) Depreciation & Amortisations	17.69	10.07
e) Other Expenditure	39.81	35.31
f) Total	525.74	427.14
3. Profit from Operations before Other Income, Interest & Exceptional Items	109.44	91.62
4. Other Income		
5. Profit before Interest & Exceptional Items (3 + 4)	109.44	91.62
6. Interest	40.76	47.59
7. Profit after interest but before Exceptional Items (5-6)	68.68	44.03
8. Exceptional Items		
9. Profit (+)/Loss(-) from Ordinary Activities before tax (7 + 8)	68.68	44.03
10. Tax expenses	15.81	9.83
11. Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9 - 10)	52.87	34.20
12. Extra Ordinary Items		
13. Net Profit (+)/ Loss(-) for the period (11-12)	52.87	34.20
14. Paid-up equity share capital (Face Value of the Share shall be indicated) (Rs. 10/- each)	61.89	37.25
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	317.11	121.37
16. Earnings Per Share (EPS)		
- Basic EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	9.43	17.91
- Diluted EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	9.43	17.91
- Basic EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	9.43	17.91
- Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	9.43	17.91
17. Public Shareholding :		
- Number of Shares	38257907	13706029
- Percentage of Shareholding	61.81	36.79
18. Promoters and Promoter Group Shareholding (non-encumbered) :		
- Number of shares	23634107	23545020
- Percentage of shares (as a % of the to total shareholding of promoter and promoter group)	100.00	100.00
- Percentage of shares (as a % of the to total share capital of the company)	38.19	63.21

Consolidated figures of the Company and its subsidiaries for the year :		
Consolidated Net Sales / Income from operations & other Income	635.18	518.76
Consolidated Net Profit	52.87	34.20
Consolidated EPS	9.43	17.91
STATEMENT OF ASSETS & LIABILITIES :		
SOURCES OF FUNDS :		
SHAREHOLDERS' FUNDS		
Share Capital	61.89	37.25
Reserves & Surplus	317.11	121.36
LOAN FUNDS	474.40	420.69
DEFERRED TAX	9.75	7.63
TOTAL	863.15	586.93
APPLICATION OF FUNDS :		
FIXED ASSETS	275.21	170.89
INVESTMENTS	5.67	1.99
(A) CURRENT ASSETS LOANS & ADVANCES		
Inventories	340.65	240.11
Sundry Debtors	275.16	193.05
Cash & Bank	25.80	17.61
Loans & Advances	53.70	28.96
(B) CURRENT LIABILITIES & PROVISIONS		
NET CURRENT ASSETS (A) - (B)	491.21	376.49
MISC. EXPENDITURE	91.06	37.56
TOTAL	863.15	586.93

Notes :

1. The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 13th August 2011.
2. During the year the Company has : Filed eight Drug Master Files (DMF) with USFDA, one Canadian DMF, nine Certificate of Suitability (COS) with EDQM and seven process patent for Non-beta molecule with Indian Patent Office.
3. There were twenty investor complaints received during of the year. No investor complaint was pending at the end of the year.
4. The company operates in only one Business Segment.
5. Figures of the previous year have been rearranged/regrouped wherever necessary.

For Parabolic Drugs Ltd.

sd/-

Pranav Gupta
Mg. Director

Place : Chandigarh
Date : 13th August, 2011